We demonstrated that dynamic changes of CEA, CA125, CYFRA21-1, and SCC-Ag were associated with the efficacy and prognosis of late-stage NSCLC patients treated with PD-1/PD-L1 inhibitors. The gene discussed is MUC16; the disease is non-small cell lung carcinoma.